ABT-239 is an H 3-receptor antagonist developed by Abbott, which is currently being investigated as a treatment for ADHD, Alzheimer's disease, and schizophrenia.
ABT-239 is an H 3-receptor antagonist developed by Abbott. It has stimulant and nootropic effects, and is currently being investigated as a treatment for ADHD, Alzheimer's disease, and schizophrenia.